# US 2021/0340545 A1 · Methods and compositions for prevention and treatment of respiratory infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0340545 A1 - Document ID: US20210340545A1 - Status: Published application - Kind: A1 - Application number: 17/306,515 - Filed: 2021-05-03 - Published: 2021-11-04 - Earliest claimed: 2020-05-04 - Assignees: UpRNA, LLC - Applicants: UpRNA, LLC - Inventors: David DEAMER - Web page: https://patentgrep.com/patent/US20210340545A1 ## CPC - C12N 15/1131: {against viruses} - A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)} - A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions} - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates - A61K 31/09: having two or more such linkages - A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 47/12: Carboxylic acids; Salts or anhydrides thereof - C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids} - C12N 2310/14: interfering nucleic acids [NA] - C12N 2320/32: Special delivery means, e.g. tissue-specific - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract This technology relates in part to methods and compositions for treatment or prevention of infections, including but not limited to respiratory infections. The methods and compositions can include lung surfactants, detergents, antivirals, siRNA, and nicotinamide adenine dinucleotide (NAD) boosting agents. ## Claims ### Claim 1 A composition, comprising: (a) a pulmonary surfactant; (b) a fatty acid; (c) a liposome; and (d) small interfering RNA (siRNA). ### Claim 2 (depends on 1) The composition of claim 1, wherein the liposome comprises one or more antivirals. ### Claim 3 (depends on 1) The composition of claim 1, wherein the liposome comprises the siRNA. ### Claim 4 (depends on 1) The composition of claim 1, wherein the siRNA targets a nucleic acid of an infectious agent. ### Claim 5 (depends on 4) The composition of claim 4, wherein the nucleic acid is an RNA. ### Claim 6 (depends on 5) The composition of claim 5, wherein the RNA is a messenger RNA (mRNA). ### Claim 7 (depends on 1) The composition of claim 1 that is formulated for prevention or treatment of a respiratory infection associated with an infectious agent. ### Claim 8 (depends on 7) The composition of claim 7, wherein the infectious agent is a virus. ### Claim 9 (depends on 8) The composition of claim 8, wherein the virus is a coronavirus. ### Claim 10 (depends on 9) The composition of claim 9, wherein the coronavirus is SARS-CoV-2. ### Claim 11 (depends on 1) The composition of claim 1, wherein the pulmonary surfactant comprises dipalmitoylphosphatidylcholine (DPPC). ### Claim 12 (depends on 1) The composition of claim 1, wherein the pulmonary surfactant comprises phosphatidylglycerol (PG). ### Claim 13 (depends on 1) The composition of claim 1, wherein the pulmonary surfactant comprises hexadecanol. ### Claim 14 (depends on 1) The composition of claim 1, wherein the pulmonary surfactant comprises tyloxapol. ### Claim 15 (depends on 1) The composition of claim 1, wherein the fatty acid is a C10-C18 fatty acid. ### Claim 16 (depends on 1) The composition of claim 1, wherein the fatty acid is a saturated fatty acid. ### Claim 17 (depends on 1) The composition of claim 1, wherein the fatty acid is a monounsaturated fatty acid. ### Claim 18 (depends on 1) The composition of claim 1, wherein the fatty acid is a polyunsaturated fatty acid. ### Claim 19 (depends on 1) The composition of claim 1, wherein the fatty acid is myristic acid. ### Claim 20 (depends on 1) The composition of claim 1, wherein the fatty acid is palmitic acid. ### Claim 21 (depends on 1) The composition of claim 1 that is formulated for prophylactic administration. ### Claim 22 (depends on 1) The composition of claim 1 that is formulated for administration as an aerosol. ### Claim 23 (depends on 1) The composition of claim 1, comprising a nicotinamide adenine dinucleotide (NAD) booster. ### Claim 24 (depends on 23) The composition of claim 23, wherein the NAD booster comprises nicotinamide mononucleotide (NMN) or a salt thereof. ### Claim 25 (depends on 23) The composition of claim 23, wherein the NAD booster comprises nicotinamide mononucleotide (NMN), a prodrug thereof, or a salt thereof. ### Claim 26 (depends on 23) The composition of claim 23, wherein the pulmonary surfactant comprises the NAD booster. ### Claim 27 A method of treating or preventing a respiratory infection, comprising administering to a subject in need thereof a composition comprising: (a) a pulmonary surfactant; (b) a fatty acid; (c) a liposome; and (d) small interfering RNA (siRNA), in an amount that is effective for treatment or prevention of the respiratory infection.